Pyridostigmine enhances, but does not normalise, the GH response to GH-releasing hormone in obese subjects. por Castro, R, Vieira, J, Chacra, A, Besser, G, Grossman, AB, Lengyel, A

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk. por Bethel, M, Chacra, A, Deedwania, P, Fulcher, G, Holman, R, Jenssen, T, Kahn, SE, Levitt, N, McMurray, J, Califf, R, Raptis, SA, Thomas, L, Sun, J, Haffner, S

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk por Bethel, M, Chacra, A, Deedwania, P, Fulcher, G, Holman, R, Jenssen, T, Kahn, SE, Levitt, N, McMurray, J, Califf, R, Raptis, SA, Thomas, L, Sun, J, Haffner, S

Updated risk factors should be used to predict development of diabetes. por Bethel, M, Hyland, K, Chacra, A, Deedwania, P, Fulcher, G, Holman, R, Jenssen, T, Levitt, N, McMurray, J, Boutati, E, Thomas, L, Sun, J, Haffner, S, NAVIGATOR Study Group

Effect of valsartan on the incidence of diabetes and cardiovascular events. por McMurray, J, Holman, R, Haffner, S, Bethel, M, Holzhauer, B, Hua, T, Belenkov, Y, Boolell, M, Buse, J, Buckley, B, Chacra, A, Chiang, F, Charbonnel, B, Chow, C, Davies, M, Deedwania, P, Diem, P, Einhorn, D, Fonseca, V, Fulcher, G, Gaciong, Z, Gaztambide, S, Giles, T, Horton, E, Ilkova, H

Effect of nateglinide on the incidence of diabetes and cardiovascular events. por Holman, R, Haffner, S, McMurray, J, Bethel, M, Holzhauer, B, Hua, T, Belenkov, Y, Boolell, M, Buse, J, Buckley, B, Chacra, A, Chiang, F, Charbonnel, B, Chow, C, Davies, M, Deedwania, P, Diem, P, Einhorn, D, Fonseca, V, Fulcher, G, Gaciong, Z, Gaztambide, S, Giles, T, Horton, E, Ilkova, H